Boothbay Fund Management’s Soleno Therapeutics SLNO Stock Holding History

Boothbay Fund Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-140,000	Closed	-$6.48M	–	2444
2025 Q4	$6.48M	Buy	140,000 +75,000	+115%	+$4.11M	0.1%	229
2025 Q3	$4.39M	Sell	65,000 -518,400	-89%	-$38.4M	0.06%	341
2025 Q2	$48.9M	Buy	583,400 +505,500	+649%	+$37.8M	0.95%	9
2025 Q1	$5.57M	Buy	+77,900	New	+$3.79M	0.15%	193
2024 Q4	–	Sell	-32,100	Closed	-$1.62M	–	1879
2024 Q3	$1.62M	Buy	+32,100	New	+$1.54M	0.04%	592
2024 Q2	–	Sell	-21,600	Closed	-$924K	–	1830
2024 Q1	$924K	Buy	21,600 +16,000	+286%	+$724K	0.02%	780
2023 Q4	$225K	Buy	+5,600	New	+$159K	0.01%	1294
2020 Q3	–	Sell	-88	Closed	-$294K	–	1198
2020 Q2	$294K	Buy	+88	New	+$3.81K	0.02%	701

Boothbay Fund Management's SLNO Position: Q2 2026 in Review

Boothbay Fund Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 124,519 shares — an estimated $4.17M sold.

Boothbay Fund Management first reported a position in SLNO in Q2 2020 and held it in 17 quarters. The position peaked at $5.65M in Q1 2024. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Boothbay Fund Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Boothbay Fund Management sold 124,519 Soleno Therapeutics shares in Q2 2026, an estimated $4.17M.
Boothbay Fund Management first reported a position in Soleno Therapeutics in Q2 2020 and held it in 17 quarters.
Boothbay Fund Management's Soleno Therapeutics position peaked at $5.65M in Q1 2024.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.